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Little is known on the long-term validity of reference equations used in the calculation of FEV1
and FEV1/FVC predicted values.
This survey assessed the prevalence of chronic airflow obstruction in a population-based
sample and how it is influenced by: (i) the definition of airflow obstruction; and (ii) equations
used to calculate predicted values. Subjects aged 45 or more were recruited in health preven-
tion centers, performed spirometry and fulfilled a standardized ECRHS-derived questionnaire.
Previously diagnosed cases and risk factors were identified. Prevalence of airflow obstruction
was calculated using: (i) ATS-GOLD definition (FEV1/FVC < 0.70); and (ii) ERS definition (FEV1/
FVC < lower limit of normal) with European Community for Coal and Steel (ECCS) reference
equations and with predicted values derived from the presumably normal fraction of the stud-
ied population.
A total of 5008 subjects (4764 adequate datasets) were studied. Prevalence of airflow
obstruction was 8.71% with ATS-GOLD definition and 6.40% with ERS definition and ECCS pre-
dicted values. The ERS definition with predicted values derived from the studied populationneumologie et Re´animation, Hoˆtel-Dieu de Paris, 1 Parvis Notre Dame, F-75181 Paris 04, France. Tel.:
8.
.aphp.fr (N. Roche).
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Diagnosis of chronic airflow obstruction 1569provided a 7.96% prevalence. Severity distribution of airflow obstruction was also influenced by
the equation used to calculate predicted values of FEV1.
Prevalence and severity of chronic airflow obstruction are influenced not only by the defini-
tion used but also by equations used to calculate predicted FEV1/FVC and FEV1 values. These
equations likely need to be periodically revised.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is one of the
leading causes of mortality, handicap and health care costs
worldwide,1,2 but remains largely underdiagnosed.3,4
Recent spirometric studies from industrialized countries
found a prevalence of COPD with airflow obstruction
(GOLD -global initiative on obstructive lung diseases- stage
1) between 4 and 10%.5,6 Such data are lacking in France.5
Higher figures have been found when airflow obstruction is
defined according to the absolute value of the ratio of
forced expiratory volume in one second to forced vital
capacity (FEV1/FVC < 0.70, ‘‘ATS-GOLD definition’’) than
when the lower limit of normal of FEV1/FVC ratio is consid-
ered (‘‘ERS definition’’).6e10
Besides, in their joint guidelines on lung function
testing, the European Respiratory Society and American
Thoracic Society (ERS and ATS) emphasize the need for
developing and updating local reference equations for
calculation of predicted values of lung function variables.
Indeed, most reference equations currently used in Europe
were developed more than 20 years ago.11
The present study was designed:
(i) To assess the impact of the definition of airflow
obstruction on prevalence: FEV1/FVC < 0.70 or
lower limit of normal (LLN) of the ratio.
(ii) To determine how the choice of reference equations
(i.e., European Community for Coal and Steel or
study-derived equations) for calculation of predicted
values of FEV1 and FEV1/FVC values influences the
prevalence and severity distribution of airflow
obstruction.
(iii) To estimate the prevalence of chronic airflow
obstruction (CAO) in French subjects visiting preven-
tion centers. The proportion of previously
undiagnosed cases and identified risk factors were
also described.Materials and methods
Design of the survey
This was a cross-sectional survey in all consecutive subjects
presenting to health centers for routine preventive visits
during an 8-month period. In France, these visits are
offered by the public health coverage system (‘‘social
security’’) to all subjects aged 45 years or more. Participat-
ing centers were harmoniously distributed on the French
territory. The sample was built according to national data
on age and sex distribution in the general population ofthe considered age range. Subjects filled a standardized
auto-questionnaire and FEV1 and FVC were measured by
a technician who was not aware of answers to the question-
naire. All subjects received an information note before
their participation. The study was approved by the ethics
committee of Nancy university hospital, France.
Questionnaire
Data obtained from each individual included usual socio-
demographic and anthropometrical description, informa-
tion on clinical symptoms, associated chronic diseases and
presumptive diagnosis, and previous assessment of lung
function.
The questionnaire was derived from the European
Community Respiratory Health Survey (ECRHS) question-
naire.12 Three questions were added to this questionnaire:
1. Did a doctor ever measure your breathing capacity? 2.
Did a doctor ever tell you that you had chronic bronchi-
tis/chronic bronchial obstruction? 3. Are you currently fol-
lowed by a doctor for chronic bronchitis? Answers on
cough and sputum production allowed to assign each sub-
ject to one of four groups: no cough and no expectoration,
chronic cough (CC), chronic expectoration (CE) and chronic
bronchitis (CB), as defined by chronic productive cough
lasting at least 3 months per year during the last 2 consec-
utive years. These groups were mutually exclusive.
A subject was considered as a never-smoker if he
smoked less than 50 cigarettes during his entire life, and
as an ex-smoker if he stopped smoking more than 1 year
ago. Each subject’s mean daily (cigarettes per day) and
cumulative consumption (pack-years) were established.
Based on answers to the questionnaire, a history or the
presence of bronchiectasis or heart failure was recorded as
comorbidities.8 Patients were classified as asthmatics if
they declared having asthma as confirmed by a physician
or if they declared having asthma without confirmation by
a physician AND reported the occurrence, during the previ-
ous year, of exercise-induced paroxysmal dyspnea, dysp-
nea-induced awakening or breathlessness with wheezing.13
Spirometry, predicted values, definition and
severity of airflow obstruction
Spirometry
Spirometry was performed by specifically trained techni-
cians using daily calibrated spirometers under BTPS condi-
tions. Three spirometers were used: Spirograph Booster
(EMO International, La Rochelle, France), Spirolyser SPL
100 (FIM SA, France) and Spiro analyser 2120 (Vitalograph,
UK). All fulfilled ATS and ERS standards and were calibrated
daily using 3 L syringes.
Table 1 Description of the studied population
N (%) unless
otherwise indicated
Sex ratio M/F 0.92 (2290/2474)
Age (years) 59.9  10.1
45e54 38.0%
55e64 26.8%
65e74 23.5%
75 & more 11.6%
Cumulative smoking of current and ex-smokers
(pack-years category, % of total population)
1e14 816 (40.9%)
15e24 510 (25.6%)
25 669 (33.5%)
Daily cigarette consumption
1 50 (2.4%)
2e20 1722 (81.9%)
21 331 (15.7%)
Occupational exposure
to dusts, gas, fumes
1423 (30.3%)
Chronic cough and sputum production
No cough nor expectoration 4142 (86.9%)
Chronic cough only 310 (6.5%)
Chronic expectoration only 127 (2.7%)
Chronic cough þ expectoration 185 (3.9%)
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ducible (variation <200 ml) measurements of FEV1 were
required. Then the best values of FEV1 and FVC from tech-
nically adequate maneuvers were selected for analysis.
Predicted values
Predicted values for FEV1/FVC and FEV1 were first calcu-
lated using European Community for Coal and Steel equa-
tions (ECCS):11,14 these equations are (H is height in m
and A is age in years): for calculation of predicted values
of FEV1/FVC: in men: 0.18A þ 87.21 (residual standard
deviation: 7.17); in women: 0.19A þ 89.10 (residual stan-
dard deviation: 6.51); for calculation of FEV1: in men:
4.30H  0.029Ae2.49 (residual standard deviation: 0.51);
in women: 3.95H  0.025Ae2.60 (residual standard devia-
tion: 0.38). In addition, equations for calculation of the
predicted values of FEV1/FVC and FEV1 were obtained for
men and women using multiple linear regression with age
and height as independent variables in the presumably nor-
mal fraction of the population. Three sets of criteria were
used to define this fraction of the population: (i) subjects
with no symptoms (nZ 2064); (ii) subjects with no symp-
toms and no known respiratory or cardiac disease
(nZ 1886); and (iii) subjects with no symptoms, no known
respiratory of cardiac disease and no smoking history
(nZ 1046).15 Lower limits of normal (LLNZ predicted
value e 1.64 residual standard deviation) obtained with
these three reference population were compared.
Definition of airflow obstruction
Three definitions of airflow obstruction were used: FEV1/
FVC < 0.70 (‘‘ATS-GOLD definition’’),1 FEV1/FVC < LLN
with predicted values calculated with ECCS reference
equations (‘‘ERS definition’’)11 and FEV1/FVC < LLN with
predicted values calculated using regression equations
derived from the presumably normal fraction of the studied
population, as defined above (‘‘study definition’’).
Severity of airflow obstruction
Severity of airflow obstruction was categorized using the
ATS-ERS-GOLD classification:1,2 stage 1, FEV1  80% of pre-
dicted value; stage 2, 50%  FEV1 < 80%; stage 3,
FEV1 < 50%. For subjects with airflow obstruction according
to ATS-GOLD and ERS definitions, ECCS predicted values of
FEV1 were used. For those with airflow obstruction
according to the study definition, FEV1 predicted values
were calculated using equations derived from the presum-
ably normal fraction of the population (see above).
Statistical analysis
Sample size calculation was performed considering an
expected prevalence of airflow obstruction of about 5%,
an allowed risk of error of 0.5% of this percentage, and
a possible analysis on two strata; 4500 files had to be
analyzed. The predicted proportion of files with missing
data or technically inadequate spirometry was estimated at
about 10%. Thus, 5000 subjects had to be recruited.
Analysis was performed using Statview 5 and SAS
softwares (SAS Institute, Cary, NC, USA). Results are ex-
pressed as percentages or means  one standard deviation.Percentages have been compared by two-way and multiway
frequency analysis, and means by analysis of variance and
t-test.9
Results
Characteristics of the studied population (Table 1)
A total of 5008 subjects participated in the survey during an
8-month recruitment period. Adequate data were available
in 4764 subjects (95.1%). This population differed slightly
from the projected sample (national statistics data) on
sex (greater proportion of men: 48.1 versus 45.8%) and
age (smaller proportion of people aged more than 75 years:
11.6 versus 19.2%).
Already known chronic respiratory diseases were
reported with the following frequency: asthma in 9.1% of
subjects, chronic airflow obstruction in 2.6% and chronic
bronchitis in 5.8%.
Predicted values of FEV1/FVC and FEV1 derived
from the presumably normal fraction of the
population
LLN obtained from FEV1/FVC and FEV1 regression equations
did not significantly differ according to how the presumably
normal fraction of the studied population was defined: for
example, mean LLN for FEV1/FVC ratio was the same in
the three populations used to derive prediction equations,
Table 2 Subjects with a low FEV1/FVC ratio according to the definition used and smoking status (whole population)
All Never-smokers Ex-smokers Current smokers
Whole population, N 4764 2297 1473 862
ATS-GOLD definitiona 415/4764 152/2297 139/1473 108/862
8.71% 6.62% 9.44% 12.53%
[7.87e9.47] [5.65e7.69] [8.02e11.01] [10.44e14.87]
ERS definitiona 305/4764 110/2297 97/1473 95/862
6.40% 4.79% 6.58% 11.02%
[5.73e7.12] [3.97e5.72] [5.40e7.94] [9.06e13.24]
Study definitiona 379/4764 143/2297 129/1473 96/862
7.96% 6.23% 8.76% 11.14%
[7.21e8.74] [5.29e7.27] [7.39e10.28] [9.16e13.97]
Patients without known lung
or heart disease, N
3794 1834 1164 690
ATS-GOLD definitiona 266/3794 96/1834 90/1164 73/690
7.01% 5.23% 7.73% 10.58%
[6.23 e 7.86] [4.28e6.33] [6.30e9.37] [8.45e13.04]
ERS definitiona 191/3794 66/1834 59/1164 66/690
5.03% 3.60% 5.07% 9.57%
[4.37e5.77] [2.82 e 4.53] [3.92 e 6.45] [7.54e11.93]
Study definitiona 243/3794 89/1834 85/1164 63/690
6.40% 4.85% 7.30% 9.13%
[5.66e7.22] [3.94e5.91] [5.91e8.91] [7.15e11.46]
a ATS-GOLD definition: FEV1/FVC < 0.70; ERS definition: FEV1/FVC < 88% predicted in men, 89% predicted in women, predicted values
from ERS equations; Study definition: FEV1/FVC < {predicted e 1.64 RSD}, with predicted values and residual standard deviation from
the presumably normal fraction of the studied population. Data are numbers (percentage of the corresponding population) [95%
confidence interval of the prevalence rate].
Diagnosis of chronic airflow obstruction 1571i.e. 0.66 in men and 0.69 in women. Thus, the largest sam-
ple was selected (nZ 1036 men, 1028 women with no respi-
ratory symptom). In that sample, equations for calculation of
FEV1/FVC predicted values were: in men, 0.114A þ 86.14;
in women, 0.080A þ 85.15. Residual standard deviations
were 6.00 in men, 5.97 in women. For FEV1, regression equa-
tions were: in men, 3.904H  0.031Ae2.569; in women:
2.589H  0.025Ae0.887. Residual standard deviations were
0.52 in men and 0.35 in men.Prevalence and severity of chronic airflow
obstruction (Tables 2 and 3)
Symptoms of chronic bronchitis were present in 3.9% of sub-
jects, among whom most subjects did not exhibit airflow
obstruction (97%). Prevalence of chronic airflow obstruction
was influenced by the definition used. It was of the same
magnitude with the ATS-GOLD definition and the ‘‘study
definition’’. The ERS definition gave a smaller prevalence
(Table 2).
In the majority of patients with chronic airflow obstruc-
tion, the disease was categorized as stage 1 (Table 3).
Depending on the definition used to diagnose airflow
obstruction and on the reference equation used to calcu-
late predicted FEV1, there were small differences in the
repartition of patients according to disease severity. These
tendencies were observed in the three sub-groups of smok-
ing status (data not shown).For all subsequent analysis, airflow obstruction was
defined by FEV1/FVC < 0.7.Prevalence versus previous diagnosis
In the non-asthmatic population with symptoms of chronic
bronchitis (nZ 150), a previous diagnosis of respiratory dis-
ease (named chronic bronchitis of chronic airflow
obstruction by the subjects) was reported by three sub-
jects. Among the 295 subjects with airflow obstruction,
eight reported such a diagnosis.Risk factors
Prevalence of chronic airflow obstruction was influenced
by smoking status but 17.2% of non-asthmatic subjects
with airflow obstruction were never smokers, and the
prevalence of FEV1/FVC < 0.70 was 5.3% in never smokers
(Table 2). Occupational exposure to dusts, gas, toxic com-
pounds or fumes were reported by about 30% of subjects.
In the population without already known chronic respira-
tory or heart disease, such exposures were associated
with a significant increase in chronic bronchitis (2.5% of
the non-exposed versus 4.0% of the exposed subjects,
pZ 0.011) and chronic airflow obstruction (6.4 versus
8.2%, respectively, pZ 0.047).
Table 3 Distribution of % predicted FEV1 in subjects with
airflow obstruction
Definition of
airflow
obstruction
FEV1
(% predicted)
Number in the category/
number of subjects
with airflow obstruction
according to the
considered definition
ATS-GOLD
definitiona
80% 245/415Z 59.0%
[50e80] 150/415Z 36.1%
[30e50] 18/415Z 4.3%
<30% 2/415Z 0.5%
ERS
definitiona
80% 154/287Z 53.7%
[50e80] 115/287Z 40.1%
[30e50] 16/287Z 5.6%
<30% 2/287Z 0.7%
Study
definitiona
80% 232/421Z 55.1%
[50e80] 150/421Z 35.6%
[30e50] 37/421Z 8.8%
<30% 2/421Z 0.5%
Predicted values were calculated using ECCS equations for
subjects with airflow obstruction according to ERS and ATS-
GOLD definitions and study equations for subjects with airflow
obstruction according to the study definition.
a ATS-GOLD definition: FEV1/FVC < 0.7; ERS definition: FEV1/
FVC < 88% predicted in men, 89% predicted in women; study
definition: FEV1/FVC < predicted value e 1.64 residual stan-
dard definition, with predicted value derived from the presum-
ably normal fraction of the studied population.
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In this sample of 4764 subjects visiting health prevention
centers, the prevalence of airflow obstruction among non-
asthmatics differed according to the definition and pre-
diction equation used, ranging between 6 and 9%. Severity
distribution also varied depending on the equation used to
calculate predicted values. FEV1 was >50% predicted in
most subjects with airflow obstruction. In the vast majority
of these subjects, no airway disease had been previously di-
agnosed. Finally, tobacco smoking and occupational expo-
sures could be identified as risk factors for airflow
obstruction in that population.
Limitations of the study
Some limitations of the study have to be addressed.
Firstly, the study population should not be considered as
representative of the French general population: the pro-
portion of subjects with respiratory symptoms and/or
a known diagnosis of COPD and/or moderate-to-severe
airflow obstruction was probably underestimated, since
these patients are usually symptomatic and followed by
a physician and, thus, do not visit prevention centers
(healthy worker effect). However, the high prevalence of
chronic airflow obstruction is in line with other studies
using spirometry in developed countries, although we
observed a marked under-representation of severe
cases.3,4,9,16 As in these studies, a significant proportionof non-asthmatic subjects with airflow obstruction were
never smokers, and reported occupational exposures.17,18
Secondly, as in many prevalence studies in the popula-
tion, we used pre-bronchodilator spirometry to assess the
prevalence and severity of airflow obstruction, which does
not conform to recent guidelines on COPD. Indeed, it has
been shown that pre-bronchodilator spirometry may over-
estimate the prevalence of COPD by about 20e35%,19 and
post-bronchodilator reference values have been recently
developed in Norway.20 However, French health prevention
centers are not allowed to deliver any kind of medication.
In addition, the use of pre-bronchodilator values is in line
with several recent epidemiological studies such as those
by De Marco et al.12,21 In their most recent paper, these
authors conclude that the use of pre-bronchodilator values
exposes to a risk of overestimating the prevalence of COPD.
They also show that this risk is minimized by exclusion of
asthmatic subjects. For this reason, all analyses were per-
formed in the whole population, in non-asthmatics only
and in subjects with no known heart or respiratory disease.
Finally, it must be outlined that the use of pre versus post-
bronchodilator values does not alter the value of compari-
sons between reference equations or definitions of airflow
obstruction, which correspond to the main purpose of the
paper.
Influence of the definition of airflow obstruction
Prevalence of airflow obstruction was greater with ATS-
GOLD definition (FEV1/FVC < 0.70) than with ERS definition
based on predicted values calculated using ECCS equations.
Surprisingly, the ATS-GOLD definition provided results
similar to those obtained with the study definition, which
was based on predicted values calculated using equations
derived from the presumably normal fraction of the studied
population.
Previous studies also found higher numbers of patients
with airflow obstruction with ATS-GOLD than with ERS
definition.7e10 It was suggested that these discrepancies
were related to an overestimation of the proportion of
older subjects with mild airflow obstruction when the
0.70 cut-off is used, since FEV1/FVC normal values decrease
with age. Data reported here also suggest that ERS refer-
ence equations may not be applicable in all European pop-
ulations and may need local or regional validation and
periodical revision, which confirms ERS/ATS guidelines.
Other reference equations could have been tested, but
we chose to limit the analysis to ECCS equations since: (i)
they still represent the most frequently used equations in
Europe; and (ii) they have been derived from a European
rather than a north-American population.
Underdiagnosis of airflow obstruction
A vast majority of detected cases of chronic airflow
obstruction previously ignored that they suffered from
this illness. This high figure may be at least in part
explained by the mode of recruitment, symptomatic and
severe subjects with known respiratory disease being less
likely to visit prevention centers. Nevertheless, a marked
underdiagnosis of COPD was also reported by several
Diagnosis of chronic airflow obstruction 1573authors3e5,9,16,22 and may be due to the poor predictive
values of symptoms.23,24
A major issue is the significance of a low FEV1/FVC ratio
(corresponding to ‘‘stage 1’’ COPD) in asymptomatic
subjects: are these subjects at risk of developing marked
airflow obstruction and respiratory handicap? Or is this
low ratio just a statistical artifact? As recently published,
clinical data from the present study show that even mild
undiagnosed airflow obstruction is associated to increased
dyspnea, work loss and altered quality of life.25 Only
a few studies assessed the rate of decline in FEV1 according
to the value of the FEV1/FVC ratio in subjects with an ini-
tially normal FEV1. In the OLIN longitudinal studies, FEV1
decline was 33 ml/year in the whole study population and
43 ml/year in incident cases of mild COPD.26 In the study
by Burrows et al., FEV1/FVC ratio was a strong predictor
of subsequent lung function decline.27 More recently,
Enright et al. found similar results with the FEV1/FEV6
ratio.28 However, further longitudinal studies, or analysis
of data from existing studies clearly remains to be per-
formed to assess disease progression in patients with stage
1 COPD.
In conclusion, this study found a high prevalence of
previously undiagnosed airflow obstruction in subjects
visiting prevention centers, despite a low proportion of
subjects with symptoms and severe lung function impair-
ment. Differences in prevalence and severity distribution
with the definition of airflow obstruction and reference
equations used confirm the need for: (i) homogenizing the
definitions of airflow obstruction used for teaching, com-
munication, clinical practice or research purposes; and (ii)
revisiting equations used to determine predicted normal
values of spirometry variables.Acknowledgements
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